MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MPN PROGRESSion Registry is a U.S.-based, prospective, non-interventional cohort that follows adults with WHO 2022–defined myeloproliferative neoplasms to collect long-term clinical outcomes, treatment patterns, symptom burden, quality of life, and healthcare utilization. It enrolls a broad range of MPN subtypes, including PV, ET, primary and secondary MF, pre-PMF, MPN-U, accelerated/blast-phase MPN, post-MPN AML, and MDS/MPN overlap, and includes patients who have had stem cell or bone marrow transplants. The registry integrates structured EHR extraction, patient-reported outcome surveys, medical claims data, and potential future linkages with external disease registries to build a multimodal real-world dataset. Participants are expected to enroll over at least five years, with many followed for ten years or longer to characterize disease trajectories and long-term outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years or older at the time of enrollment.
* Confirmed diagnosis of a myeloproliferative neoplasm (MPN), including one or more of the following subtypes, according to WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplants (SCTs) or bone marrow transplants (BMTs):
* Polycythemia vera (PV)
* Essential thrombocythemia (ET)
* Primary myelofibrosis (PMF)
* Secondary myelofibrosis (post-ET or post-PV MF)
* Pre-fibrotic primary myelofibrosis (pre-PMF)
* Myeloproliferative neoplasm-unclassifiable (MPN-U)
* Myeloproliferative neoplasm, accelerated phase (MPN-AP)
* Myeloproliferative neoplasm, blast phase (MPN-BP)
* Post-MPN acute myeloid leukemia (AML)
* Myelodysplastic syndrome (MDS)/MPN overlap syndrome
* Myeloproliferative neoplasm, blast phase (MPN-BP)
* Ability to provide informed consent electronically or through a legally authorized representative.
* Willingness to share health information, including electronic health records (EHR), laboratory values, and survey responses.
* Willingness to complete periodic patient-reported outcome (PRO) surveys and symptom tracking assessments.

Exclusion Criteria:

* Individuals under 18 years of age.
* Inability to provide informed consent, either directly or through a legally authorized representative.
* Currently enrolled in an interventional clinical trial where participation would interfere with the ability to participate in this observational registry (based on investigator or sponsor judgment).
* Any condition that, in the judgment of the study team, would make participation in the registry infeasible or unsafe.

Where it's running

• MPN Research Foundation
  Chicago, Illinois, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Raajit Rampal, MD, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Stephanie Scobey, MPN, BS, RN
• Email: sscobey@mpnrf.org
• Phone: 847-449-5307

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT12396 for people with high-risk polycythemia vera or myelofibrosis

  The team will try the oral drug PRT12396 in people with high-risk polycythemia vera or myelofibrosis to find safe doses and look for early signs of benefit.

  Recruiting at 22 sites Phase 1 Prelude Therapeutics Incorporated · Los Angeles, California and 21 other locations · NCT07469891

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Comparing ASTX727 with and without Iadademstat for advanced blood cancers

  This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 31 other locations · NCT06661915

• Evaluating the safety and effectiveness of bomedemstat for blood disorders

  This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.

  Recruiting at 18 sites Phase 3 Merck Sharp & Dohme LLC · Ann Arbor, Michigan and 20 other locations · NCT06351631

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.